Elevance Health, Inc.
439.95USD
-5.3300 (-1.20%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on ELV.
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | $2▼ | $2.47 | 1 | 1 |
| Next quarter | $12.26▲ | $12.03 | 1 | 0 |
| Current year | $29.08▲ | $27.16 | 3 | 0 |
| Next year | $30.22▲ | $29.63 | 2 | 1 |
Beat in 4 of the last 4
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-09-30 | $4.69 | $6.99 | +2.30 (+48.9%) |
| 2026-06-30 | $6.21 | $7.45 | +1.24 (+20.0%) |
| 2026-03-31 | $10.81 | $12.58 | +1.77 (+16.4%) |
| 2025-12-31 | $3.09 | $3.33 | +0.24 (+7.7%) |
334 ratings from 41 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| TD Cowen | Maintained | Buy | $465 $495 | Oct 23, 2026 |
| UBS | Maintained | Buy | $460 $523 | Oct 22, 2026 |
| Guggenheim | Maintained | Buy | $460 $485 | Oct 22, 2026 |
| Morgan Stanley | Maintained | Equal-Weight | $404 $449 | Oct 22, 2026 |
| RBC Capital | Maintained | Sector Perform | $424 $455 | Oct 22, 2026 |
| Barclays | Maintained | Overweight | $469 $472 | Oct 22, 2026 |
| Baird | Maintained | Neutral | $393 $406 | Oct 22, 2026 |
| Guggenheim | Maintained | Buy | $455 $460 | Oct 12, 2026 |
| Barclays | Maintained | Overweight | $457 $469 | Oct 7, 2026 |
| Bernstein | Maintained | Outperform | $482 $488 | Jul 17, 2026 |
| Leerink Partners | Maintained | Market Perform | $364 $395 | Jul 17, 2026 |
| RBC Capital | Maintained | Sector Perform | $439 $424 | Jul 16, 2026 |
| Wells Fargo | Maintained | Overweight | $492 $473 | Jul 16, 2026 |
| Guggenheim | Maintained | Buy | $399 $455 | Jul 16, 2026 |
| Barclays | Maintained | Overweight | $480 $457 | Jul 16, 2026 |
| Baird | Maintained | Neutral | $331 $393 | Jul 16, 2026 |
| TD Cowen | Maintained | Buy | $400 $465 | Jul 14, 2026 |
| Truist Securities | Maintained | Buy | $450 $475 | Jul 14, 2026 |
| Wells Fargo | Maintained | Overweight | $391 $492 | Jul 13, 2026 |
| RBC Capital | Maintained | Sector Perform | $358 $439 | Jul 9, 2026 |
| Cantor Fitzgerald | Maintained | Overweight | $400 $450 | Jul 7, 2026 |
| Bernstein | Maintained | Outperform | $424 $482 | Jul 2, 2026 |
| Mizuho | Maintained | Outperform | $435 $465 | Jun 8, 2026 |
| JP Morgan | Maintained | Overweight | $411 $476 | Jun 8, 2026 |
| B of A Securities | Maintained | Buy | $435 $460 | Jun 4, 2026 |
74 filings from 24 insiders · 14 buy / 3 sell over 6m
Officers and directors of ELV, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.
| Insider | Action | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Kaye MarkOfficer, EVP & CFO | Sell | 273 | $447.19 | $122k | Oct 22, 2026 |
| Kaye MarkOfficer, EVP & CFO | Sell | 827 | $446.05 | $369k | Oct 22, 2026 |
| Kaye MarkOfficer, EVP & CFO | Sell | 160 | $444.85 | $71k | Oct 22, 2026 |
| Kaye MarkOfficer, EVP & CFO | Sell | 440 | $443.81 | $195k | Oct 22, 2026 |
| Kaye MarkOfficer, EVP & CFO | Sell | 480 | $442.61 | $212k | Oct 22, 2026 |
| Kaye MarkOfficer, EVP & CFO | Sell | 2.3k | $441.34 | $1.03M | Oct 22, 2026 |
| Kaye MarkOfficer, EVP & CFO | Sell | 1.7k | $440.44 | $758k | Oct 22, 2026 |
| Kaye MarkOfficer, EVP & CFO | Sell | 1.2k | $439.25 | $510k | Oct 22, 2026 |
| Kaye MarkOfficer, EVP & CFO | Sell | 240 | $438.22 | $105k | Oct 22, 2026 |
| Kaye MarkOfficer, EVP & CFO | Sell | 560 | $437.07 | $245k | Oct 22, 2026 |
| Kaye MarkOfficer, EVP & CFO | Sell | 1.7k | $436.20 | $724k | Oct 22, 2026 |
| Kaye MarkOfficer, EVP & CFO | Sell | 321 | $435.25 | $140k | Oct 22, 2026 |
| Kaye MarkOfficer, EVP & CFO | Sell | 400 | $434.00 | $174k | Oct 22, 2026 |
| Kaye MarkOfficer, EVP & CFO | Grant | 2.6k | — | — | Oct 2, 2026 |
| Kaye MarkOfficer, EVP & CFO | Tax | 4.2k | $386.43 | $1.61M | Oct 2, 2026 |
| Wessling Erin MOfficer, EVP & Chief Legal Officer | Tax | 255 | $414.78 | $106k | Sep 3, 2026 |
| Wessling Erin MOfficer, EVP & Chief Legal Officer | Tax | 94 | $405.84 | $38k | Sep 2, 2026 |
| Craig Ryan ROfficer, EVP & Chief HR Officer | Tax | 144 | $405.84 | $58k | Sep 2, 2026 |
| PERU RAMIRO GDirector | Buy | 1.0k | $366.05 | $366k | Jul 17, 2026 |
| BOUDREAUX GAIL A KOZIARAChief Executive Officer | Buy | 2.7k | $366.41 | $1.00M | Jul 17, 2026 |
No analyst notes on ELV yet.
Analyst Ratings
21 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 2 | 12 | 8 | 0 | 0 | Buy2.27 |
| 1 mo ago | 2 | 12 | 8 | 0 | 0 | Buy2.27 |
| 2 mo ago | 3 | 12 | 7 | 0 | 0 | Buy2.18 |
| 3 mo ago | 3 | 12 | 7 | 0 | 0 | Buy2.18 |
Members whose judged calls on ELV have played out most reliably.
No settled calls on ELV yet. Nobody has filed a call with a deadline on it.
A member is listed once they have three judged calls on a name.
A call with a target is judged on whether the price reaches it by the deadline, counting each day's high (a buy) or low (a sell) from the day after the call was made. A call without one is judged on whether the price at the close on the deadline is higher (a buy) or lower (a sell) than the price the call was made at: the live price when it was saved, for a call made with Make a call, or the last close before the day it was filed, for a call made in a note. Not against the market or an index.
A percentage appears once five calls have reached their deadline. A target reached sooner is shown as played out early, and counts toward the percentage when its deadline passes, because a miss cannot be known before then.
A member’s prediction, judged on price history · not investment advice